Market Cap
$5.4B
PTCT
PTC THERAPEUTICS, INC.
$63.46 ▼ -1.04%
Prev close $64.13Market cap$5.4B
ConsensusStrong Buy
12-mo target$101.79 (+60.4%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)31 New Institutional Positions19 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on PTCT right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (81%)
Inst. Holders
50 funds
Inst. Value
$6.9B
Inst. Activity
31 buys / 19 sells
Insider Activity
$0.00 buy / $13.5M sell
Insider Net $
-$13.5M
SEC Reports
15
Price chart 30d -11.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 25, 2026 other
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., Sept. 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced t
Sep 17, 2026 Insider
SCHMERTZLER MICHAEL sold 9,624 shares
Director @ $67.83 ($652.8K)
Sep 17, 2026 Insider
SCHMERTZLER MICHAEL sold 376 shares
Director @ $68.45 ($25.7K)
Sep 16, 2026 Insider
Aug 22, 2026 SEC SCHMERTZLER MICHAEL sold 2,994 shares
Director @ $66.58 ($199.3K)
Two insiders at PTC Therapeutics sold a total of $459K in open-market sales over a 7-day window. Director Michael Schmer
CLUSTER — Impact 2/10
Three PTC Therapeutics insiders, including the CFO and Chief Technical Ops Officer, sold a total of $1.40M in stock over
CLUSTER — Impact 3/10
PTC Therapeutics reported Q2 2026 EPS of -$0.03, a 108% miss versus the $0.38 consensus, while revenue of $295.4M matche
PRESS-RELEASE — Impact 7/10
Jun 30, 2026 Inst.
TORONTO DOMINION BANK — TRIM
2,165,846 shares ($176.7M)
Analyst ratings buy % +19.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
81% rate it Buy or better · 21 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 22, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | 49% |
| Aug 14, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| Aug 13, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
| Jul 31, 2026 | Morgan Stanley | MAINTAIN | Overweight | 55% |
| Jul 31, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
| Jul 20, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
| Jul 16, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | 49% |
| Jul 7, 2026 | RBC Capital | MAINTAIN | Sector Perform | 55% |
| May 27, 2026 | Jefferies | UPGRADE | Buy | 53% |
| May 8, 2026 | TD Cowen | UPGRADE | Buy | 56% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 11 | 3 | 1 | 0 | 81% | |
| Aug 1, 2026 | 6 | 11 | 3 | 1 | 0 | 81% | |
| Jul 1, 2026 | 6 | 11 | 3 | 1 | 0 | 81% | |
| Jun 1, 2026 | 5 | 11 | 4 | 1 | 0 | 76% | |
| May 1, 2026 | 4 | 11 | 6 | 1 | 0 | 68% | |
| Apr 1, 2026 | 4 | 10 | 6 | 1 | 0 | 67% | |
| Mar 1, 2026 | 6 | 10 | 5 | 1 | 0 | 73% | |
| Feb 1, 2026 | 6 | 10 | 5 | 1 | 0 | 73% |
Price targets
Where 14 covering analysts think PTCT trades over the next 12 months.
$101.79 +60.4% upside Strong Buy
Current$63.46 Low$70.00 Median$101.00 High$137.00 14 analysts
$70.00$137.00
Analyst rating Buy· 1.7/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
15 SEC filing reports analyzed · 1 bullish, 3 bearish, 0 mixed, 11 neutral · avg impact 3.5/10.
NEUTRALCLUSTER2/10
Two insiders at PTC Therapeutics sold a total of $459K in open-market sales over a 7-day window. Dir
Aug 22, 2026
NEUTRALCLUSTER3/10
Three PTC Therapeutics insiders, including the CFO and Chief Technical Ops Officer, sold a total of
Jul 17, 2026
BEARISHPRESS-RELEASE7/10
PTC Therapeutics reported Q2 2026 EPS of -$0.03, a 108% miss versus the $0.38 consensus, while reven
Jul 16, 2026
NEUTRALCLUSTER2/10
Two PTCT insiders — the Chief Technical Operations Officer and the EVP & CLO — sold a combined ~$267
Jul 14, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 25, 2026
other
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., Sept. 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept. 22, 2026, the company approved non-st
Sep 21, 2026
m_and_a
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
– Completion of BLA submission expected in Q4 2026 – WARREN, N.J., Sept. 21, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announc
Sep 9, 2026
Clinical Trial
A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria
Phase Phase 3 — COMPLETED
Sep 9, 2026
clinical_trial_readout
Results Pending: PTC923 (Phase 3) — Completed 50d ago
Trial: A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria Sponsor: PTC Therapeutics Phase: Phase 3 | Completed: 2026-07-21 Condit
Aug 17, 2026
ftd
FTD: PTCT — 15,042 shares ($1.1M) failed to deliver
Settlement: 20260817, Price: $71.70, FTD Value: $1,078,511.4, PTC THERAPEUTICS INC COM STK (
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.38 | $0.30–$0.48 | 102.2% | +22.6% | 0↑ 2↓ | $0.3B | 3 |
| Next Q | $0.30 | $0.15–$0.50 | 116.7% | +21.6% | 0↑ 3↓ | $0.3B | 3 |
| Current FY | $1.71 | $1.50–$1.82 | -77.6% | +7.1% | 2↑ 1↓ | $1.3B | 3 |
| Next FY | $2.68 | $2.25–$3.04 | 56.5% | +7.1% | 1↑ 2↓ | $1.4B | 3 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.380 | — |
| 7d ago | $0.310 | +0.070 |
| 30d ago | $0.310 | +0.070 |
| 60d ago | $0.537 | -0.157 |
| 90d ago | $0.473 | -0.093 |
Institutional ownership
Which big funds own PTCT (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $6.9B total value (84,092,718 shares) as of 2026-Q2. Top holders: NOMURA, BlackRock,, RTW. Net buying activity: 31 institutions added/increased vs 19 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| NOMURA ASSET MANAGEMENT CO LTD | 0 | $0.00 | 0.0% | — |
| BlackRock, Inc. | 13,964,554 | $1.1B | 16.6% | — |
| RTW INVESTMENTS, LP | 7,746,415 | $631.9M | 9.2% | — |
| Jupiter Topco LLC | 7,236,402 | $590.2M | 8.6% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4,928,111 | $402.0M | 5.9% | — |
| STATE STREET CORP | 4,598,952 | $375.1M | 5.5% | — |
| WELLINGTON MANAGEMENT GROUP LLP | 4,128,273 | $336.7M | 4.9% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,739,127 | $305.0M | 4.4% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 2,207,376 | $180.1M | 2.6% | — |
| TORONTO DOMINION BANK | 2,165,846 | $176.7M | 2.6% | TRIM -28.4% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| TORONTO DOMINION BANK | TRIM | 3,025,963 | 2,165,846 | -28.4% | $176.7M |
| WESTFIELD CAPITAL MANAGEMENT CO LP | NEW | — | 1,956,156 | — | $159.6M |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | NEW | — | 1,722,688 | — | $140.5M |
| DRIEHAUS CAPITAL MANAGEMENT LLC | ADD | 1,015,772 | 1,440,107 | +41.8% | $117.5M |
| FULLER & THALER ASSET MANAGEMENT, INC. | NEW | — | 1,156,819 | — | $94.4M |
| MORGAN STANLEY | ADD | 674,134 | 1,103,675 | +63.7% | $90.0M |
| CITADEL ADVISORS LLC | ADD | 385,199 | 747,822 | +94.1% | $61.0M |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 533,300 | 723,500 | +35.7% | $59.0M |
| MARSHALL WACE, LLP | ADD | 460,638 | 704,787 | +53.0% | $57.5M |
| JPMORGAN CHASE & CO | ADD | 346,017 | 684,042 | +97.7% | $56.1M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
7 insiders, 50 transactions. Net -$13.5M — $0.00 bought, $13.5M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 17, 2026 | SCHMERTZLER MICHAEL | Director | SELL | 9,624 | $67.83 | $652.8K |
| Sep 17, 2026 | SCHMERTZLER MICHAEL | Director | SELL | 376 | $68.45 | $25.7K |
| Sep 16, 2026 | SCHMERTZLER MICHAEL | Director | SELL | 2,994 | $66.58 | $199.3K |
| Sep 16, 2026 | SCHMERTZLER MICHAEL | Director | SELL | 7,006 | $67.35 | $471.9K |
| Sep 10, 2026 | SCHMERTZLER MICHAEL | Director | SELL | 10,000 | $67.34 | $673.4K |
| Sep 9, 2026 | SCHMERTZLER MICHAEL | Director | SELL | 572 | $68.67 | $39.3K |
| Sep 9, 2026 | SCHMERTZLER MICHAEL | Director | SELL | 9,428 | $67.79 | $639.1K |
| Aug 27, 2026 | SCHMERTZLER MICHAEL | Director | SELL | 11,890 | $71.55 | $850.7K |
| Aug 27, 2026 | SCHMERTZLER MICHAEL | Director | SELL | 610 | $72.22 | $44.1K |
| Aug 26, 2026 | SCHMERTZLER MICHAEL | Director | SELL | 6,874 | $72.74 | $500.0K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for PTCT.
Shares short
9,738,919
Settlement Sep 15, 2026
Change vs prior
-0.9%
Semi-monthly cycle
Days to cover
11.0
At avg daily volume
Of shares outstanding
≈11.7%
Estimate — not % of float
All PTCT filing & press-release reports (15)
- CLUSTER reportAug 22, 2026
- CLUSTER reportJul 17, 2026
- PRESS-RELEASE reportJul 16, 2026
- CLUSTER reportJul 14, 2026
- CLUSTER reportJul 9, 2026
- CLUSTER reportJun 26, 2026
- 8-K reportJun 16, 2026
- 8-K reportJun 9, 2026
- CLUSTER reportMay 19, 2026
- CLUSTER reportMay 15, 2026
- 8-K reportApr 28, 2026
- DEFA14A reportApr 20, 2026
- CLUSTER reportApr 8, 2026
- CLUSTER reportMar 13, 2026
- CLUSTER reportMar 9, 2026